CClinicalTrials.gg
Active, not recruitingNCT07624981DIAGNO-KAUpdated Jun 3, 2026

Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions

An observational study in Skin Cancer and Diagnostic, sponsored by Centre Hospitalier Régional Metz-Thionville. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Centre Hospitalier Régional Metz-Thionville · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 3 months ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
140
Ages
18 Years and older
Sex
All
01

Study summary

Actinic keratoses are precancerous skin lesions that are the most common among all cancers and precancerous conditions in fair-skinned populations. The distinctive feature of these actinic keratoses is that some progress into skin cancers known as cutaneous carcinomas, while others regress spontaneously; currently, there is no way to distinguish between them, either through clinical observation or biological methods. The goal of the Diagno-KA project is to develop a diagnostic test that would distinguish between actinic keratoses that progress to cancer-so they can be surgically removed early (before they become severe and metastasize)-and those that regress, thereby avoiding unnecessary surgical intervention (to prevent scarring).

02

Conditions studied

  • Skin Cancer
  • Diagnostic
03

In context

Skin Neoplasms

582 studies on the registry are indexed under Skin Neoplasms; 114 are open to participants now.

This study's enrollment of 140 is below the median of 200 across 134 observational studies indexed under Skin Neoplasms.

Browse Skin Neoplasms studies →

Lead sponsor

Centre Hospitalier Régional Metz-Thionville is the lead sponsor of 118 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with skin carcinomas and actinic keratoses

Inclusion criteria

  • patients with skin carcinomas and actinic keratoses

Exclusion criteria

Exclusion Criteria:

  • minor patient
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
140 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Biomarker validation

    Time frame: Until the end of the study on average 2 years

07

Study locations

1 site
  • CHR Metz-Thionville
    Metz, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07624981
Lead sponsor
Centre Hospitalier Régional Metz-Thionville
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Feb 1, 2026
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jun 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion